Efficacy of oral moxidectin against susceptible and resistant isolates of Dirofilaria immitis in dogs

BACKGROUND: Monthly topical and sustained-release injectable formulations of moxidectin are currently marketed; however, an oral formulation, while approved at a dose of 3 μg/kg, is not currently marketed in the United States. Although resistance of heartworms to all macrocyclic lactone (ML) heartwo...

Descripción completa

Detalles Bibliográficos
Autores principales: McTier, Tom L., Six, Robert H., Pullins, Aleah, Chapin, Sara, McCall, John W., Rugg, Douglas, Maeder, Steven J., Woods, Debra J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688394/
https://www.ncbi.nlm.nih.gov/pubmed/29143634
http://dx.doi.org/10.1186/s13071-017-2429-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688394/
https://www.ncbi.nlm.nih.gov/pubmed/29143634
http://dx.doi.org/10.1186/s13071-017-2429-5

Ejemplares similares